

Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (as of October 31, 2022)

Proposed indication, etc.	Partnering	Region (planned)	Cell type	status
Pediatric congenital athymia (RETHYMIC®)	Duke University	Global	Cultured thymus tissue	Launched in March 2022 (U.S.)
AMD (age-related macular degeneration)	Healios RIKEN	Global	Allo iPS cell-derived retinal pigment epithelium	Preparing to start clinical study (Japan)
Parkinson's disease (Designated as a "SAKIGAKE")	Kyoto University CiRA	Global	Allo iPS cell-derived dopamine neural progenitor cells	In progress: investigator-initiated study (Phase 1 / 2 study) (Japan) Preparing to start clinical study (U.S.)
Retinitis pigmentosa	RIKEN	Global	Allo iPS cell-derived photoreceptor (3D)	In progress: clinical research
Spinal cord injury	Keio University Osaka National Hospital	Global	Allo iPS cell-derived neural progenitor cells	In progress: clinical research (Sub-Acute Phase) In progress: pre-clinical study (Chronic Phase)
Kidney failure	Jikei University Bios	Japan, North America	Auto/ Allo iPS cell-based induced nephron progenitor cells (organ)	In progress: pre-clinical study

Aim to start clinical study in FY2022

Aim to launch in FY2024 *

* Launch schedule is based on our goal pending agreement with partners